Scientific ReportsImmunologyPeer-reviewed journal article
Characterization of Collaborative Cross mouse founder strain CAST/EiJ as a novel model for lethal COVID-19
Candice N. BakeriD, Debra K. Duso, Naga Rama KothapalliiD, Tricia Hart, Sean Casey, Tres S. CookenhamiD, Larry W. Kummer, Janine HvizdosiD, Kathleen G. LanzeriD, Purva Vats, Priya Shanbhag, Isaac Bell, Mike Tighe, Kelsey L. TravisiD, Frank M. SzabaiD, Jeffrey M. HarderiD, Olivia BedardiD, Natalie Oberding, Jerrold Michael WardiD, Mark D. AdamsiD, Cathleen M. LutziD, Shelton S. BradrickiD, William W. ReileyiD, Nadia A RosenthaliD
Abstract
Mutations in SARS-CoV-2 variants of concern (VOCs) have expanded the viral host range beyond primates, and a limited range of other mammals, to mice, affording the opportunity to exploit genetically diverse mouse panels to model the broad range of responses to infection in patient populations. Here we surveyed responses to VOC infection in genetically diverse Collaborative Cross (CC) founder strains. Infection of wild-derived CC founder strains produced a broad range of viral burden, disease susceptibility and survival, whereas most other strains were resistant to disease despite measurable lung viral titers. In particular, CAST/EiJ, a wild-derived strain, developed high lung viral burdens, more severe lung pathology than seen in other CC strains, and a dysregulated cytokine profile resulting in morbidity and mortality. These inbred mouse strains may serve as a valuable platform to evaluate therapeutic countermeasures against severe COVID-19 and other coronavirus pandemics in the future.
- Citations
- 7
- FWCI
- 2.16
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19
S. Robertson, O. Bedard, … S. Best·bioRxiv·Sep 17, 2021
- A mouse-adapted SARS-CoV-2 strain replicating in standard laboratory mice.
X. Montagutelli, M. Prot, … E. Simon-Loriere·bioRxiv·Jul 10, 2021
- B.1.1.7 and B.1.351 variants are highly virulent in K18-ACE2 transgenic mice and show different pathogenic patterns from early SARS-CoV-2 strains
P. Radvak, H. J. Kwon, … H. Xie·bioRxiv·Jun 5, 2021
- Differential pathogenesis of SARS-CoV-2 variants of concern in human ACE2-expressing mice
J. P. Natekar, H. Pathak, … M. Kumar·bioRxiv·Apr 4, 2022
- ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
- Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
A. Muruato, M. Vu, … V. D. Menachery·bioRxiv·May 3, 2021